Koji Umemura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Koji Umemura has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Seitaro Terakura
Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
12 shared publications - Hitoshi Kiyoi
Department of Hematology and Oncology Nagoya University Graduate School of Medicine Nagoya Japan
11 shared publications - Shingo Okuno
Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
11 shared publications - Yoshitaka Adachi
Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
11 shared publications - Kazuyuki Shimada
Department of Hematology and Oncology Nagoya University Graduate School of Medicine Nagoya Japan
10 shared publications - Kanae Imai
Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
9 shared publications
Latest Publications
- Open Access
- 13 April 2026
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 9 (7) , e202503550
BATF3 regulates differentiation of CD8 + T lymphocytes and memory differentiation program
CD8 + T lymphocytes differentiate from effector to memory cells after antigen clearance, with prolonged IL-2 production characterizing functional cytotoxic T lymphocytes (CTLs). To identify transcription factors associated with sustained IL-2 production, we compared influenza virus–specific and cytomegalovirus-specific CTLs, identifying Basic Leucine Zipper ATF-Like Transcription Factor 3 (BATF3) as a key candidate. BATF3 overexpression significantly enhanced cell proliferation in both virus-specific CTLs and CD19 chimeric antigen receptor T (CAR-T) cells while reducing cytokine production. Among AP-1 transcription factor family members, BATF and BATF3 demonstrated similar functions during effector phase expansion, but BATF3 exhibited distinct roles in promoting memory cell formation. ATAC-seq analysis revealed that BATF3 overexpression dynamically regulates chromatin accessibility, affecting diverse cellular processes including cytoskeletal organization, metabolic pathways, and survival signaling. BATF and BATF3 showed comparable kinetics until peak expansion, but BATF3 specifically facilitated the transition from effector to memory phase, up-regulating memory-associated genes while down-regulating exhaustion markers. These findings establish BATF3 as a master regulator of CD8 + T-cell fate determination through chromatin remodeling, offering therapeutic targets for enhancing CAR-T cell persistence in immunotherapy.
- 13 April 2026
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 9 (7) , e202503550
Open AccessBATF3 regulates differentiation of CD8 + T lymphocytes and memory differentiation program
CD8 + T lymphocytes differentiate from effector to memory cells after antigen clearance, with prolonged IL-2 production characterizing functional cytotoxic T lymphocytes (CTLs). To identify transcription factors associated with sustained IL-2 production, we compared influenza virus–specific and cytomegalovirus-specific CTLs, identifying Basic Leucine Zipper ATF-Like Transcription Factor 3 (BATF3) as a key candidate. BATF3 overexpression significantly enhanced cell proliferation in both virus-specific CTLs and CD19 chimeric antigen receptor T (CAR-T) cells while reducing cytokine production. Among AP-1 transcription factor family members, BATF and BATF3 demonstrated similar functions during effector phase expansion, but BATF3 exhibited distinct roles in promoting memory cell formation. ATAC-seq analysis revealed that BATF3 overexpression dynamically regulates chromatin accessibility, affecting diverse cellular processes including cytoskeletal organization, metabolic pathways, and survival signaling. BATF and BATF3 showed comparable kinetics until peak expansion, but BATF3 specifically facilitated the transition from effector to memory phase, up-regulating memory-associated genes while down-regulating exhaustion markers. These findings establish BATF3 as a master regulator of CD8 + T-cell fate determination through chromatin remodeling, offering therapeutic targets for enhancing CAR-T cell persistence in immunotherapy.
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models
Supplemental Figure S3. Analysis of differentiation markers of CAR-T cells. Each CAR-T cells and tEGFR-T cells were stimulated with CD19/CD37 positive Raji cells at a 1:5 ratio every 7 days and stained for CD62L, CD45RA, CCR7, CD27 and CD28. A, B, Summary data of the percentage of CD45RA-/CD62L+ central memory T (TCM) cell fraction (A) and CD45RA-/CD62L- effecter memory T (TEM) cell fraction (B). C–E, Summary data of the percentage of CCR7-/CD27+/CD28+ early TEM cell fraction (C), CCR7-/CD27+/CD28- late TEM cell fraction (D) and CCR7-/CD27-/CD28- effecter T cell fraction (E). Data represent mean ± SEM from five different donors (two-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001).
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models
Supplemental Figure S3. Analysis of differentiation markers of CAR-T cells. Each CAR-T cells and tEGFR-T cells were stimulated with CD19/CD37 positive Raji cells at a 1:5 ratio every 7 days and stained for CD62L, CD45RA, CCR7, CD27 and CD28. A, B, Summary data of the percentage of CD45RA-/CD62L+ central memory T (TCM) cell fraction (A) and CD45RA-/CD62L- effecter memory T (TEM) cell fraction (B). C–E, Summary data of the percentage of CCR7-/CD27+/CD28+ early TEM cell fraction (C), CCR7-/CD27+/CD28- late TEM cell fraction (D) and CCR7-/CD27-/CD28- effecter T cell fraction (E). Data represent mean ± SEM from five different donors (two-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001).
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models
Supplemental Figure S3. Analysis of differentiation markers of CAR-T cells. Each CAR-T cells and tEGFR-T cells were stimulated with CD19/CD37 positive Raji cells at a 1:5 ratio every 7 days and stained for CD62L, CD45RA, CCR7, CD27 and CD28. A, B, Summary data of the percentage of CD45RA-/CD62L+ central memory T (TCM) cell fraction (A) and CD45RA-/CD62L- effecter memory T (TEM) cell fraction (B). C–E, Summary data of the percentage of CCR7-/CD27+/CD28+ early TEM cell fraction (C), CCR7-/CD27+/CD28- late TEM cell fraction (D) and CCR7-/CD27-/CD28- effecter T cell fraction (E). Data represent mean ± SEM from five different donors (two-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001).
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models
Supplemental Figure S3. Analysis of differentiation markers of CAR-T cells. Each CAR-T cells and tEGFR-T cells were stimulated with CD19/CD37 positive Raji cells at a 1:5 ratio every 7 days and stained for CD62L, CD45RA, CCR7, CD27 and CD28. A, B, Summary data of the percentage of CD45RA-/CD62L+ central memory T (TCM) cell fraction (A) and CD45RA-/CD62L- effecter memory T (TEM) cell fraction (B). C–E, Summary data of the percentage of CCR7-/CD27+/CD28+ early TEM cell fraction (C), CCR7-/CD27+/CD28- late TEM cell fraction (D) and CCR7-/CD27-/CD28- effecter T cell fraction (E). Data represent mean ± SEM from five different donors (two-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001).
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Data from Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models
Chimeric antigen receptor T (CAR-T) cells targeting multiple antigens (Ag), may reduce the risk of immune escape following the loss of the target Ag and further increase the efficacy of treatment. We developed dual-targeting CAR-T cells that target CD19 and CD37 Ags and evaluated their antitumor effects. CD19/CD37 dual CAR-T cells were generated using cotransduction and simultaneous gene transfer of two types of lentiviral vectors transferring CD19CAR or CD37CAR genes, including the intracellular domains of CD28 and CD3ζ signaling domains. These dual CAR-T cells contained three fractions: CD19/CD37 bispecific CAR-T cells, single CD19CAR-T cells, and single CD37CAR-T cells. In the functional evaluation of CAR-T cells in vitro, CD19/CD37 dual CAR-T cells showed adequate proliferation and cytokine production in response to CD19 and CD37 antigen stimulation alone or in combination. Evaluation of intracellular signaling revealed that dual CAR-T cell–mediated signals were comparable with single CAR-T cells in response to CD19- and CD37-positive B-cell tumors. Although the cytotoxicity of CD19/CD37 dual CAR-T cells in both CD19- and CD37-positive B-cell tumors was similar to that of single CD19 and CD37CAR-T cells, against CD19 and CD37 Ag-heterogeneous tumor, dual CAR-T cells demonstrated significantly superior tumor lysis compared with single CAR-T cells. Furthermore, CD19/CD37 dual CAR-T cells effectively suppressed Ag-heterogeneous Raji cells in a xenograft mouse model. Collectively, these results suggest that CD19/CD37 dual CAR-T cells may be effective target-Ag-loss B-cell tumor models in vitro and in vivo, which represents a promising treatment for patients with relapsed/refractory B-cell malignancies.
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models
Chimeric antigen receptor T (CAR-T) cells targeting multiple antigens (Ag), may reduce the risk of immune escape following the loss of the target Ag and further increase the efficacy of treatment. We developed dual-targeting CAR-T cells that target CD19 and CD37 Ags and evaluated their antitumor effects. CD19/CD37 dual CAR-T cells were generated using cotransduction and simultaneous gene transfer of two types of lentiviral vectors transferring CD19CAR or CD37CAR genes, including the intracellular domains of CD28 and CD3ζ signaling domains. These dual CAR-T cells contained three fractions: CD19/CD37 bispecific CAR-T cells, single CD19CAR-T cells, and single CD37CAR-T cells. In the functional evaluation of CAR-T cells in vitro, CD19/CD37 dual CAR-T cells showed adequate proliferation and cytokine production in response to CD19 and CD37 antigen stimulation alone or in combination. Evaluation of intracellular signaling revealed that dual CAR-T cell–mediated signals were comparable with single CAR-T cells in response to CD19- and CD37-positive B-cell tumors. Although the cytotoxicity of CD19/CD37 dual CAR-T cells in both CD19- and CD37-positive B-cell tumors was similar to that of single CD19 and CD37CAR-T cells, against CD19 and CD37 Ag-heterogeneous tumor, dual CAR-T cells demonstrated significantly superior tumor lysis compared with single CAR-T cells. Furthermore, CD19/CD37 dual CAR-T cells effectively suppressed Ag-heterogeneous Raji cells in a xenograft mouse model. Collectively, these results suggest that CD19/CD37 dual CAR-T cells may be effective target-Ag-loss B-cell tumor models in vitro and in vivo, which represents a promising treatment for patients with relapsed/refractory B-cell malignancies.
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary FIgure S2 from Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models
Supplemental Figure S2. Evaluation of cytokine production against tumor cells isolated from patients who relapsed after CAR-T cell therapy. A, Expression of CD19, CD20, and CD37 in diffuse large B-cell lymphoma cells from a relapsed patient after a treatment with tisagenlecleucel. B, Intracellular IL-2 or IFN-γ positive cells after stimulation with the patient tumor cells at an E:T ratio 1:1 for 4 h.
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary FIgure S2 from Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models
Supplemental Figure S2. Evaluation of cytokine production against tumor cells isolated from patients who relapsed after CAR-T cell therapy. A, Expression of CD19, CD20, and CD37 in diffuse large B-cell lymphoma cells from a relapsed patient after a treatment with tisagenlecleucel. B, Intracellular IL-2 or IFN-γ positive cells after stimulation with the patient tumor cells at an E:T ratio 1:1 for 4 h.
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models
Supplemental Figure S1. CD19 and CD37 expression of EBV-LCL. EBV-LCL was stained with CD19-PE and CD37-FITC mAb, respectively. Grey tinted area indicated isotype control staining.
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models
Supplemental Figure S1. CD19 and CD37 expression of EBV-LCL. EBV-LCL was stained with CD19-PE and CD37-FITC mAb, respectively. Grey tinted area indicated isotype control staining.
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary FIgure S2 from Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models
Supplemental Figure S2. Evaluation of cytokine production against tumor cells isolated from patients who relapsed after CAR-T cell therapy. A, Expression of CD19, CD20, and CD37 in diffuse large B-cell lymphoma cells from a relapsed patient after a treatment with tisagenlecleucel. B, Intracellular IL-2 or IFN-γ positive cells after stimulation with the patient tumor cells at an E:T ratio 1:1 for 4 h.
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary FIgure S2 from Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models
Supplemental Figure S2. Evaluation of cytokine production against tumor cells isolated from patients who relapsed after CAR-T cell therapy. A, Expression of CD19, CD20, and CD37 in diffuse large B-cell lymphoma cells from a relapsed patient after a treatment with tisagenlecleucel. B, Intracellular IL-2 or IFN-γ positive cells after stimulation with the patient tumor cells at an E:T ratio 1:1 for 4 h.
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Data from Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models
Chimeric antigen receptor T (CAR-T) cells targeting multiple antigens (Ag), may reduce the risk of immune escape following the loss of the target Ag and further increase the efficacy of treatment. We developed dual-targeting CAR-T cells that target CD19 and CD37 Ags and evaluated their antitumor effects. CD19/CD37 dual CAR-T cells were generated using cotransduction and simultaneous gene transfer of two types of lentiviral vectors transferring CD19CAR or CD37CAR genes, including the intracellular domains of CD28 and CD3ζ signaling domains. These dual CAR-T cells contained three fractions: CD19/CD37 bispecific CAR-T cells, single CD19CAR-T cells, and single CD37CAR-T cells. In the functional evaluation of CAR-T cells in vitro, CD19/CD37 dual CAR-T cells showed adequate proliferation and cytokine production in response to CD19 and CD37 antigen stimulation alone or in combination. Evaluation of intracellular signaling revealed that dual CAR-T cell–mediated signals were comparable with single CAR-T cells in response to CD19- and CD37-positive B-cell tumors. Although the cytotoxicity of CD19/CD37 dual CAR-T cells in both CD19- and CD37-positive B-cell tumors was similar to that of single CD19 and CD37CAR-T cells, against CD19 and CD37 Ag-heterogeneous tumor, dual CAR-T cells demonstrated significantly superior tumor lysis compared with single CAR-T cells. Furthermore, CD19/CD37 dual CAR-T cells effectively suppressed Ag-heterogeneous Raji cells in a xenograft mouse model. Collectively, these results suggest that CD19/CD37 dual CAR-T cells may be effective target-Ag-loss B-cell tumor models in vitro and in vivo, which represents a promising treatment for patients with relapsed/refractory B-cell malignancies.
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models
Chimeric antigen receptor T (CAR-T) cells targeting multiple antigens (Ag), may reduce the risk of immune escape following the loss of the target Ag and further increase the efficacy of treatment. We developed dual-targeting CAR-T cells that target CD19 and CD37 Ags and evaluated their antitumor effects. CD19/CD37 dual CAR-T cells were generated using cotransduction and simultaneous gene transfer of two types of lentiviral vectors transferring CD19CAR or CD37CAR genes, including the intracellular domains of CD28 and CD3ζ signaling domains. These dual CAR-T cells contained three fractions: CD19/CD37 bispecific CAR-T cells, single CD19CAR-T cells, and single CD37CAR-T cells. In the functional evaluation of CAR-T cells in vitro, CD19/CD37 dual CAR-T cells showed adequate proliferation and cytokine production in response to CD19 and CD37 antigen stimulation alone or in combination. Evaluation of intracellular signaling revealed that dual CAR-T cell–mediated signals were comparable with single CAR-T cells in response to CD19- and CD37-positive B-cell tumors. Although the cytotoxicity of CD19/CD37 dual CAR-T cells in both CD19- and CD37-positive B-cell tumors was similar to that of single CD19 and CD37CAR-T cells, against CD19 and CD37 Ag-heterogeneous tumor, dual CAR-T cells demonstrated significantly superior tumor lysis compared with single CAR-T cells. Furthermore, CD19/CD37 dual CAR-T cells effectively suppressed Ag-heterogeneous Raji cells in a xenograft mouse model. Collectively, these results suggest that CD19/CD37 dual CAR-T cells may be effective target-Ag-loss B-cell tumor models in vitro and in vivo, which represents a promising treatment for patients with relapsed/refractory B-cell malignancies.
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models
Supplemental Figure S1. CD19 and CD37 expression of EBV-LCL. EBV-LCL was stained with CD19-PE and CD37-FITC mAb, respectively. Grey tinted area indicated isotype control staining.
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models
Supplemental Figure S1. CD19 and CD37 expression of EBV-LCL. EBV-LCL was stained with CD19-PE and CD37-FITC mAb, respectively. Grey tinted area indicated isotype control staining.
- 12 October 2023
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 23 (3) , 381-393
Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models
Chimeric antigen receptor T (CAR-T) cells targeting multiple antigens (Ag), may reduce the risk of immune escape following the loss of the target Ag and further increase the efficacy of treatment. We developed dual-targeting CAR-T cells that target CD19 and CD37 Ags and evaluated their antitumor effects. CD19/CD37 dual CAR-T cells were generated using cotransduction and simultaneous gene transfer of two types of lentiviral vectors transferring CD19CAR or CD37CAR genes, including the intracellular domains of CD28 and CD3ζ signaling domains. These dual CAR-T cells contained three fractions: CD19/CD37 bispecific CAR-T cells, single CD19CAR-T cells, and single CD37CAR-T cells. In the functional evaluation of CAR-T cells in vitro, CD19/CD37 dual CAR-T cells showed adequate proliferation and cytokine production in response to CD19 and CD37 antigen stimulation alone or in combination. Evaluation of intracellular signaling revealed that dual CAR-T cell–mediated signals were comparable with single CAR-T cells in response to CD19- and CD37-positive B-cell tumors. Although the cytotoxicity of CD19/CD37 dual CAR-T cells in both CD19- and CD37-positive B-cell tumors was similar to that of single CD19 and CD37CAR-T cells, against CD19 and CD37 Ag-heterogeneous tumor, dual CAR-T cells demonstrated significantly superior tumor lysis compared with single CAR-T cells. Furthermore, CD19/CD37 dual CAR-T cells effectively suppressed Ag-heterogeneous Raji cells in a xenograft mouse model. Collectively, these results suggest that CD19/CD37 dual CAR-T cells may be effective target-Ag-loss B-cell tumor models in vitro and in vivo, which represents a promising treatment for patients with relapsed/refractory B-cell malignancies.
- 12 October 2023
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 23 (3) , 381-393
Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models
Chimeric antigen receptor T (CAR-T) cells targeting multiple antigens (Ag), may reduce the risk of immune escape following the loss of the target Ag and further increase the efficacy of treatment. We developed dual-targeting CAR-T cells that target CD19 and CD37 Ags and evaluated their antitumor effects. CD19/CD37 dual CAR-T cells were generated using cotransduction and simultaneous gene transfer of two types of lentiviral vectors transferring CD19CAR or CD37CAR genes, including the intracellular domains of CD28 and CD3ζ signaling domains. These dual CAR-T cells contained three fractions: CD19/CD37 bispecific CAR-T cells, single CD19CAR-T cells, and single CD37CAR-T cells. In the functional evaluation of CAR-T cells in vitro, CD19/CD37 dual CAR-T cells showed adequate proliferation and cytokine production in response to CD19 and CD37 antigen stimulation alone or in combination. Evaluation of intracellular signaling revealed that dual CAR-T cell–mediated signals were comparable with single CAR-T cells in response to CD19- and CD37-positive B-cell tumors. Although the cytotoxicity of CD19/CD37 dual CAR-T cells in both CD19- and CD37-positive B-cell tumors was similar to that of single CD19 and CD37CAR-T cells, against CD19 and CD37 Ag-heterogeneous tumor, dual CAR-T cells demonstrated significantly superior tumor lysis compared with single CAR-T cells. Furthermore, CD19/CD37 dual CAR-T cells effectively suppressed Ag-heterogeneous Raji cells in a xenograft mouse model. Collectively, these results suggest that CD19/CD37 dual CAR-T cells may be effective target-Ag-loss B-cell tumor models in vitro and in vivo, which represents a promising treatment for patients with relapsed/refractory B-cell malignancies.